Skip to Main Content

Paper Details

Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration-Resistant Prostate Cancer.
Clin Pharmacol Ther
5
2022
11-gene panel, CDK, CDK4/6, CRPC, Castration-Resistant Prostate Cancer, PDX, PHA-793887, TOP2, abiraterone-resistant cell lines, differentially expressed genes, genes, metastatic castration-resistant prostate cancer, mitoxantrone, palbociclib, patient, patient-derived xenograft, patients, topoisomerase II, tumor, tumors
Author NameAffiliation
Bo QinMayo Clinic
Alan H BryceMayo Clinic
Richard M WeinshilboumMayo Clinic
Liewei WangMayo Clinic
  • 1 - 4

Datasets

Release 1.2